Athenex, Inc. to Report Second Quarter 2019 Earnings Results on August 7, 2019
July 29 2019 - 8:00AM
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of
novel therapies for the treatment of cancer, today announced that
it will release second quarter and six-months ended June 30, 2019
financial results on Wednesday, August 7, 2019, before the market
opens, and host a conference call and live audio webcast 8:00am
Eastern Time to discuss the financial results and provide a
business update.
To participate in the call, dial 877-407-0784 (domestic) or
201-689-8560 (international) fifteen minutes before the conference
call begins and reference the conference passcode 13691069.
The live conference call and replay can also be accessed via audio
webcast at the Investor Relations section of the Company’s website,
located at http://ir.athenex.com/.
About Athenex, Inc. Founded in 2003,
Athenex, Inc. is a global clinical stage biopharmaceutical company
dedicated to becoming a leader in the discovery, development and
commercialization of next generation drugs for the treatment of
cancer. Athenex is organized around three platforms, including an
Oncology Innovation Platform, a Commercial Platform and a Global
Supply Chain Platform. The Company’s current clinical pipeline is
derived from four different platform technologies: (1) Orascovery,
based on non-absorbed P-glycoprotein inhibitor, (2) Src kinase
inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4)
Arginine deprivation therapy. Athenex’s employees worldwide are
dedicated to improving the lives of cancer patients by creating
more active and tolerable treatments. Athenex has offices in
Buffalo and Clarence, New York; Cranford, New Jersey; Houston,
Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple
locations in Chongqing, China; and Manchester, U.K. For more
information, please visit www.athenex.com.
CONTACTSInvestor Relations:Tim McCarthyManaging
Director, LifeSci Advisors, LLCDirect: 212-915-2564
Athenex, Inc.:Randoll SzeChief Financial OfficerEmail:
randollsze@athenex.com
Jacqueline LiCorporate Development and Investor RelationsEmail:
jacquelineli@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Apr 2023 to Apr 2024